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Abstract
Extracellular vesicles are cell-derived vesicles, which can transport various cargos out of cells. From their cell of
origin, the content molecules (proteins, non-coding RNAs including miRNAs, DNA and others) can be delivered
to neighboring or distant cells and as such extracellular vesicles can be regarded as vehicles of intercellular
communication or “homing pigeons”. Extracellular vesicle shuttling is able to actively modulate the tumor
microenvironment and can partake in tumor dissemination. In various diseases, including cancer, levels of
extracellular vesicle secretion are altered resulting in different amounts and/or profiles of detectable vesicular
cargo molecules and these distinct content profiles are currently being evaluated as biomarkers. Apart from
their potential as blood-derived containers of specific biomarkers, the transfer of extracellular vesicles to
surrounding cells also appears to be involved in the propagation of phenotypic traits. These interesting
properties have put extracellular vesicles into the focus of many recent studies.
Here we review findings on the involvement of extracellular vesicles in transferring traits of cancer cells to their
surroundings and briefly discuss new data on oncosomes, a larger type of vesicle. A pressing issue in cancer
treatment is rapidly evolving resistance to many initially efficient drug therapies. Studies investigating the role of
extracellular vesicles in this phenomenon together with a summary of the technical challenges that this field is
still facing, are also presented. Finally, emerging areas of research such as the analysis of the lipid composition
on extracellular vesicles and cutting-edge techniques to visualise the trafficking of extracellular vesicles are discussed.
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Background
According to an advanced PubMed search, “exosome”
has become the most cited term in publications describ-
ing any kind of vesicle [1]. However, the term exosome
only refers to vesicles generated by the inward budding
of the endosomal compartments, of which several are
forming so-called multivesicular bodies (MVBs). Many
MVBs fuse with lysosomes whereas others may fuse with
the plasma membrane, resulting in secretion of their
intraluminal vesicles [2]. Exosomes are generally distin-
guished from microvesicles by size and by origin: exo-
somes are ~30 -120 nm in size, with an endosomal origin
whereas microvesicles are >100-1000 nm and originate
from the plasma membrane (Fig. 1a). Current purification
methods unfortunately do not allow to precisely discrim-
inate between the two populations as it is very likely that
microvesicles with a size of 30–120 nm exist as well. Pro-
tein aggregates and lipoproteins might also contaminate
and confound the sample preparation. Furthermore, once
the vesicles have been released, their origin cannot be
identified as unique markers for the different vesicle types
have not been defined yet [3–5]. Because of the difficulty
to specifically discriminate exosomes from other circu-
lating vesicles, the International Society of Extracellular
Vesicles suggested to use the generic term “extracellu-
lar vesicles (EVs)” to describe vesicles isolated from the
extracellular milieu [1]. For clarity, in this review, the
term exosome mentioned in the majority of the cited
publications, will be replaced by the term “extracellular
vesicles” to be in accordance with the new guidelines.* Correspondence: stephanie.kreis@uni.lu
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Although various isolation methods exist, differential
ultracentrifugation followed by density gradient separ-
ation, electron microscopy together with protein com-
position analysis is generally considered the best so far
available workflow to isolate and characterise EVs [6].
Nevertheless, some studies where EVs were isolated by
using the less accepted “precipitation method” are also
cited here, in order to provide a complete overview of
the different topics covered in this review.
EVs were initially thought to be an expedient for cells
to remove unwanted components [7, 8]. However, recent




Fig. 1 a EV repertoire. Cells secrete distinct sub-populations of EVs and although of different origins, they overlap in size or density and often co-purify.
Exosomes are vesicles generated by the inward budding of the endosomal compartments (endocytic vesicles), which become early endosomes (EE),
several of which are forming so-called multivesicular bodies (MVBs). MVBs either fuse with lysosomes or with the plasma membrane, which results in
their secretion. In addition, cancer cells can produce larger vesicles named “large oncosomes”. Together with exosomes and microvesicles, oncosomes
contain abundant bioactive molecules, which can transfer cancer traits or be used as biomarkers. b Relative to the general EV content of normal cells
(tetraspanins, MHC molecules, proteins involved in the MVB biogenesis, heat shock proteins), cancer EVs are often enriched in specific miRNAs
or proteins. Furthermore, the membrane of cancer EVs is characterised by specific lipid species localised in lipid rafts. c Cancer cells secrete
more EVs than the corresponding healthy cells. Acidic pH and hypoxia, which often characterise the tumor microenvironment, stimulate an increased
secretion of EVs and influence the EV content, which in turn supports angiogenesis and metastasis. Additional references not previsouly cited in the
text: KRAS [99], Annexin A3 [100], TGFβ [101], Glypican 1 [102]
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more than just garbage bins. As EVs can be released by
“donor” cells and taken up by “recipient” cells, it has
been hypothesised that these vesicles broaden the cells’
repertoire to communicate and exchange signals. Several
studies have already confirmed that EVs are important
players in influencing both physiological and pathological
conditions by delivering molecules such as cytokines,
growth factors, proteins, mRNAs, miRNAs and other
non-coding RNAs to other tissues and cells [3]. The dis-
covery that EVs have a wide range of regulatory functions
and carry various endogenous cellular components made
them the most studied vesicles in recent years [9] and sev-
eral reviews covering different aspects of extracellular
vesicle biology and function have been published [9–13].
The current review focuses on new developments in
EV characterisation (lipid profiling of cancer-derived EVs)
and visualisation (imaging of EV traffic) as well as on the
potential involvement of EVs in propagating tumorigenic
properties, in particular drug resistance. Finally, technical
limitations that impede a full understanding of EV biology
and functions will be summarised.
Characterisation of EVs
Cargo and composition of EVs
The content profiles of EVs depend mainly on their par-
ental cells. The ExoCarta database (www.exocarta.org)
provides information about the EV content in different
organisms and cell types. Generally, EVs from different
cell types contain endosome-associated proteins (e.g.
Rab GTPase, SNAREs, Annexins, and flotillins), some of
which are involved in the biogenesis of MVBs (e.g. Alix
and Tsg101) [14]. Membrane proteins including tetra-
spanins (e.g. CD63, CD81, CD82, CD53, CD37 and CD9),
heat shock proteins, MHC complexes, growth factors and
many others are also present [15]. How exactly proteins
are sorted into EVs is still under investigation. The role of
ubiquitination seems controversial: in most cases, ubiqui-
tination targets the proteins destined for degradation
(upon fusion of the MVB with lysosomes) while proteins
to be exported show no ubiquitination [16]. In some other
cases, EV proteins appear to be highly ubiquitinated [17].
EVs have also been shown to contain single-stranded
DNA and transposable elements [18] as well as double-
stranded genomic DNA which might reflect the muta-
tional status of the parental tumor cell [19, 20].
The RNA content of EVs is enriched in small non-coding
RNAs including miRNAs [2]. Although the sorting mecha-
nisms are not fully understood, recent evidence suggests
that the composition of EV miRNAs differs from the one of
the cell of origin suggesting a selective sorting of miRNAs
into EVs. In this context, Villarroya-Beltri et al. [21] identi-
fied the presence of unique sequence motifs that could
prone miRNAs for sorting into EVs or for intracellular
localisation. They also demonstrated that the sumoylated
heterogeneous nuclear ribonucleoprotein A2B1 binds
miRNAs through their “EXO-motifs” and controls their
loading into EVs, thus providing an explanation for the
specific packing of certain miRNAs into EVs. In con-
trast, interesting findings from Squadrito et al. [22]
suggest a passive mechanism for miRNA export modu-
lated by cell activation-dependent changes of miRNA
target levels: EV miRNA secretion might be a mechanism
by which cells remove miRNAs in excess of their corre-
sponding targets to re-establish miRNA/mRNA homeo-
stasis. More recently McKenzie and collegues identified
Ago2 protein as a possible major player in miRNA sorting.
Indeed, they demonstrated that phosphorylation of Ago2
promoted by KRAS suppressed its secretion into EVs and
thereby the sorting of specific miRNAs [23].
The presence of regulatory miRNAs within EVs has
raised a strong interest ever since Valadi et al. [24] showed
for the first time that miRNAs in mast cell-derived EVs can
be transferred to other mast cells and be functional. Since
then, fascinating examples of intercellular communication
via miRNAs between cells in culture have been provided
[25–28]. Albeit accumulating evidence for the importance
of miRNAs in EVs, it remains uncertain whether such
miRNAs are really functional in a physiological environ-
ment and whether the concentration of secreted individual
miRNAs would be sufficient to mediate measurable endo-
crine effects. Furthermore, it is still unclear how widely this
process occurs in vivo and whether it is restricted to certain
cell types, physiological conditions or diseases or whether it
is a ubiquitous way of cell-to-cell communication. For
Williams et al. [29] the concentration of miRNAs in
biological fluids is significantly lower than in the surround-
ing cells and might be below the threshold for triggering
any significant function in vivo. The work of Chevillet et al.
[30] argues along these lines. By using a stochiometric
approach, they performed quantitative assessments of
miRNAs within EVs isolated from five different sources.
Less than one copy of a given miRNA per EV was observed
by absolute quantification through real time PCR. These
data would suggest that standard EV preparations might
not carry biologically significant numbers of miRNAs. In
accordance with this, we made a similar observation. After
successful transfer of detectable levels of miR-211-5p via
EVs isolated from melanoma patient serum samples to
miR-211-5p-negative melanoma recipient cells, we could
not detect any down-regulation of previously confirmed
target genes (unpublished data). Interestingly, in the
same cellular model 5 nM of miR-211 mimic was able
to effectively down-regulate those target genes (RAB22A,
AP1S2, M6PR) [31] suggesting that amounts of transferred
miRNAs isolated from patient sera were not sufficient to
evoke downstream effects. Moreover and apart from
quantities, other factors play a role: it is still difficult to
clearly discriminate between secreted miRNAs indicative
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of malignant processes from “contaminating” miRNAs de-
rived from platelets, erythrocytes, lymphocytes or nor-
mal cell death [32]. Among all the components of EVs,
miRNAs are one of the most controversial but also in-
teresting players in intercellular signaling and tumor
progression and their potential involvement in acquisition
and transfer of cancer cell resistance to drug treatments is
discussed in more detail below.
EVs carry lipids of a similar composition as found in
the plasma membrane of the parental cells (such as
cholesterol, ceramide and sphingomyelin) [2]. An emer-
ging field in vesicle research and more specifically in
the context of cancer, is “lipidomics” which, apart from
general lipid profiling, also studies alterations in lipid
compositions. Changes in lipid metabolism and in par-
ticular activation of de novo lipogenesis have already
been described for several cancers [33–35]. Recently,
Marien and colleagues identified a distinct lipid signa-
ture in non-small cell lung cancer. By using a mass
spectrometry-based phospho-lipidomics approach, the
authors identified 91 phospholipid species differentially
expressed in cancer versus normal tissues [36]. The dis-
tinct lipid composition of EVs coupled with the capability
of EVs to travel in biological fluids, puts lipid profiling on
the list for novel biomarker discovery. Interestingly, an en-
richment in certain lipid species in the membrane of EVs
has been reported in several publications. In this context,
Llorente et al. [37] observed a specific sorting of lipids into
EVs compared to the secreting cells. Lipid composition
analysis of metastatic prostate cancer cells and corre-
sponding EVs revealed an enrichment in glycosphingoli-
pids, cholesterol, sphingomyelin and phosphatidylserine in
EVs compared to parental cells. However, the authors did
not compare the lipid composition of these EVs to those
released from normal prostate cells. The enrichment of
specific lipids within the membrane of EVs has also been
described in colorectal cancer cells [38]. Furthermore,
Schlaepfer and colleagues observed that hypoxia triggered
triglyceride accumulation in prostate cancer cells and
corresponding EVs due to the activation of lipogenesis-
related enzymes [39]. Overall, lipidomics of EVs has
gained attention in recent years but to this day, it remains
controversial which lipids are involved in EV-mediated
cell-to-cell communication [40], also because it is a
challenge to produce pure EV preparations and to avoid
cellular lipoparticle contaminations, potentially leading
to misinterpretations. Nevertheless, standardised and
well-controlled lipid profiling of EV membranes might
be useful for the identification of new biomarkers and for
a better understanding of the biology of EV secretion.
Visualisation of EVs and EV traffic
The most common methods used to detect and charac-
terise EVs are electron microscopy (EM), dynamic light
scattering (DLS), nanoparticle tracking analysis (NTA),
fluorescence microscopy and flow cytometry (FCM). Two
standard methods are used to assess the quality of the EV
preparation: EM and either DLS or NTA. EM has the ad-
vantage that it provides the highest resolution compared
to the other methods. In addition, EM combined with
immuno-gold labeling allows for recognition of protein
markers on the surface of EVs. DLS and NTA both meas-
ure the size of particles using Brownian molecular move-
ment but NTA has, additionally, a camera documenting
the movement and light scattering of the samples [41].
Unlike previous methods, which only enable physical
characterisation of EVs in fixed samples, fluorescence mi-
croscopy visualises labelled EVs in live cell conditions/as-
says. Several fluorescent membrane dyes are used to label
purified EVs such as the PKH-67 (green) or PKH-26 (red)
linker dyes. One disadvantage of the labelling dyes is their
long half-life in vivo (from 5 to >100 days), which hinders
the dynamic tracking of EVs in vivo [42].
An alternative to labelling the membranes of EVs is to
link their protein content to TAMRA-NHS (carboxyte-
tramethylrhodamine succinimidyl ester, Biotum) [43]. In
order to label EVs released by the cells in vitro and in
vivo, EV protein marker or membrane localisation tags
(e.g. palmitoylation signal) have been fused to fluores-
cent proteins [44, 45]. Moreover, EVs from melanoma
cells were visualised in vivo using multiphoton microscopy
in orthotopic tumors using Gaussia luciferase (Gluc) [46].
Gluc was also fused to biotin (GlucB) on the surface of the
EVs, facilitating the conjugation of labeled streptavidin in
order to see the labeled EVs in vivo using fluorescence me-
diated tomography (FMT) [42]. In addition to FMT, GlucB
can also be visualised using magnetic resonance imaging
(MRI) or positron emission photography (PET) [47]. Fi-
nally, advances in flow cytometry (FCM) enhanced the
sensitivity of this technique to detect EVs. A recent, im-
proved method allows for detection of PKH-67-labelled
EVs with a comparable detection threshold as compared
to NTA [48]. FCM can also be coupled with a camera in
order to discriminate the EVs from false positive results
[49, 50] and has been applied to characterise EVs released
by mesenchymal stromal cells (MSC) using antibodies
against MSC marker proteins [51].
Lai et al. have recently succeeded to show the dynamics
of EV-mediated communication by taking advantage of
the different combination possibilities offered by fusing
enhanced green fluorescent protein (eGFP) and tandem
dimer Tomato (td Tomato) to a palmitoylation signal
(PalmGFP, PalmtdTomato) and GlucB [52]. First, EV
exchange between 2 populations of cancer cells was
visualised by labelling one with PalmGFP and the other
with PalmtdTomato [52]. Then, by combining Gluc-
labelled EV [42] and PalmtdTomato, EV uptake and EV-
mRNA translation was tracked in the recipient cells [52].
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Next, EV-packaged mRNA was monitored by tagging the
transcripts encoding PalmtdTomato to a MS2 RNA bind-
ing sequence fused with eGFP, allowing to simultaneously
visualise EV-packaged mRNA and EVs themselves. Finally,
by combining PalmtdTomato and EV-GlucB, the dynam-
ics of EV uptake and EV-mRNA translation were moni-
tored [52]. Applying completely different systems to track
EV traffic, several elegant studies by two different groups
have visualised EV uptake in living cells using both β-
galactosidase and the Cre/LoxP system. Ridder et al. used
LacZ gene as reporter gene and β-galactosidase expression
was induced in recipient cells by EV transfer. This transfer
was demonstrated in mouse tumor models and between
hematopoietic system and brain in vivo [53, 54]. This
method was the first approach to analyse the physiological
transfer of EVs in vivo and represents a step forward in
avoiding potential artifacts introduced by submitting cells
to an excess amount of isolated and labelled EVs [55]. By
using a similar approach, the expression of green fluores-
cent protein (GFP) was triggered in cells, which took up
EVs produced by tumor cells expressing the Cre recom-
binase [55, 56]: Cre-expressing melanoma cells injected
into mice were releasing EVs containing Cre mRNA,
which were then transferred to non-tumour cells in vivo
[56]. In the target cells, Cre mRNA was translated into
Cre protein and induced the expression of GFP [56]. How-
ever, this method cannot be used to assess the precise
quantification of the uptake of EVs in recipient cells [56]
as it does not allow for characterisation of transferred EVs
or the uptake mechanism of EVs [57].
Taken together, the visualisation and tracking of EV
movements has seen rapid and promising developments
in recent years. Nevertheless, all these advances will need
appropriate controls and to some degree standardisation
of protocols in order to substantiate new findings on EV
dynamics, characteristics and transfer of oncogenic traits
in physiologic contexts and their potential clinical applica-
tions. As such, these novel imaging techniques could be
combined with gene deletion or mutation strategies in
order to better understand the role of specific molecules,
which are transferred into EVs or are involved in the
loading of cargo into EVs or in the uptake of EVs by
target cells.
EVs in cancer
Cancer EVs differ from those released by healthy cells in
terms of content and quantity. An increased secretion of
EVs has been reported for different cancer cell lines and
patients [58, 59]. Some typical proteins, miRNAs and
other molecules described to be augmented in EVs re-
leased from cancer cells are presented in Fig. 1b. Acidic
pH [60, 61] and hypoxia [59, 62], hallmark properties of
many solid tumors, might be responsible for the intensi-
fication of EV production and for their altered content.
Several recent studies have investigated this phenomenon
under hypoxic conditions. An enhanced secretion of
microvesicles from mesenchymal stem cells in response to
hypoxia was reported by Zhang et al. [63]. Along these
lines, Kucharzewska et al. [64] showed that EVs derived
from glioblastoma cells grown under hypoxic conditions
were potent inducers of angiogenesis in vitro through
phenotypic modulation of endothelial cells: glioblastoma-
derived hypoxic EVs induced endothelial cells to secrete
several potent growth factors and cytokines and to stimu-
late the PI3K/AKT signaling pathway. In addition, EVs
from hypoxic prostate cancer cells enhanced invasiveness
and stemness of prostate cancer cells under normoxia and
promoted the cancer-associated fibroblast phenotype in
prostate stromal cells by targeting adherent junction
molecules [65]. Umezu and colleagues [66] provided
evidence that in endothelial cells, hypoxia-driven accel-
erated tube formation was attributable to miRNA-135b
in EVs shed from hypoxia-resistant multiple myeloma
cells. Interestingly, the EV transfer of miRNA-135b re-
sulted in the suppression of FIH-1, a negative regulator
of HIF-1α suggesting that the upregulation of HIF-1α
could enhance angiogenesis. More recently, Li et al. ob-
served increased levels of miR-21 in EVs isolated from
hypoxic oral squamous cell carcinoma. The transfer of
this miRNA in normoxic cells induced migration and
invasion both in vitro and in vivo [67]. Although the
mentioned studies of Umezu and Li provide solid evi-
dence for the reported biological effects, they did not
follow the generally accepted EV isolation procedures,
increasing the possibility of precipitating contaminants.
It is also worth mentioning that hypoxic, but not nor-
moxic tumor-derived EVs impaired NK cell function by
delivering both TGFβ and miRNA-23a [68]. In conclusion,
EVs secreted from hypoxic cancer cells seem to carry a
cargo, which supports angiogenesis and thus metastasis as
well as immunosuppression.
Cancer EVs are taken up by “recipient cells” but whether
this process occurs in a specific manner or at random is
poorly understood. Interesting findings by Hoshino et al.
showed that integrins inserted in the membrane of EVs
dictate their adhesion to specific cells in specific organs
[69]. Tumor-derived EVs taken up by specific cells based
on their integrin expression profile, were able to promote
pro-migratory and pro-inflammatory S100 gene upregula-
tion and by doing so, initiated the pre-metastatic niche in
vivo. More studies will be necessary to confirm a potential
specificity in the cellular uptake of EVs.
EVs are not the only vehicles to transfer oncogenic in-
formation. Recently, a new class of microvesicles named
oncosomes has been described. Oncosomes differ from
nano-sized EVs in terms of size (oncosomes are much
larger with a diameter of 1–10 μm) and in the biogenesis
pathway (oncosomes derive from the plasma membrane
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of cells that have acquired an amoebotic phenotype,
Fig. 1a). Di Vizio et al. [70] first introduced the term
“large oncosomes” to describe large vesicles originating
from amoeboid prostate cancer cells. The shedding of
these vesicles could be induced by EGF while bleb for-
mation in both normal prostate epithelial and stromal
cells was modest and unresponsive to EGF. Indeed, only
tumor cells seem to release quantifiable amounts of large
oncosomes that were directly correlated with their rate
of aggressiveness [71, 72]. Oncosomes, like EVs, contain
mRNAs, miRNAs and proteins. Caveolin 1, a serum bio-
marker of metastatic prostate cancer, was detected in onco-
somes and thus correlated with prostate tumor progression
in mice and discriminated patients with metastatic disease
from those with organ-confined disease [71]. Furthermore,
the oncosome-associated miR-1227 produced by prostate
cancer cells was able to induce migration of cancer-
associated fibroblasts [72]. Whether nano-sized EVs
and oncosomes share some of their molecular cargo is
still under investigation. Nevertheless, recent findings
from Minciacchi et al. revealed a different protein con-
tent in the two vesicle populations suggesting a specific
selection of proteins destined for both vesicle types
[73]. So far only a limited number of studies are avail-
able on oncosomes and more will be required in order
to better characterise the two vesicle classes in terms of
unique markers, content and function.
Contribution of EVs to drug resistance
Drug resistance of cancer cells represents a challenge in
most anti-neoplastic treatments. The development of a
resistant phenotype is considered to be multi-factorial
and mainly due to decreased drug accumulation, increased
efflux, increased biotransformation, drug compartmental-
isation, acquired genetic modification of drug targets and/
or defects in cellular pathways [74]. Recently, EVs have
been identified as new players in passing resistance onto
still sensitive cells [75, 76], which in turn might “gain”
drug resistance traits as illustrated in Fig. 2.
EV-mediated drug export
Apart from the up-regulation of efflux pumps, which
will be described below, in the establishment of drug re-
sistance, the direct sequestration of drugs into lysosomal
vesicles and EVs has also been reported. Safaei et al. [77]
have shown the lysosomal compartment to be notably
reduced in size in cisplatin-resistant human ovarian car-
cinoma cells with more EVs exporting cisplatin via this
route compared to sensitive cells.
Pulse-chase experiments with doxorubicin, a fluores-
cent anticancer drug, confirmed the hypothesis that drug
expulsion can occur via EVs. In MCF-7 cells, doxorubicin
localised in the nucleus immediately after the drug was ad-
ministered. Twenty-four hours later, nuclear fluorescence
was significantly decreased and most of the visible
doxorubicin was present in EVs associated with the cell
periphery indicating the active sorting of drugs into
vesicles [78]. Furthermore, Federici et al. [61] demonstrated
that EVs purified from supernatants of melanoma cells
treated with cisplatin contained detectable levels of the
drug. HPLC analysis indicated that cisplatin within EVs was
in its unmetabolised form suggesting that EVs might in-
corporate the drug immediately after the uptake by the cell.
More recently Koch et al. were able to detect anthracyclines
in EVs from diffuse large B cell lymphoma cells lines. Inter-
estingly, knocking down the ATP-transporter A3 (ABCA3)
augmented intracellular retention of the drugs, thus in-
creasing their cytostatic effects [79].
EV-mediated miRNA export
In addition to the above-mentioned mechanisms, miRNAs
packaged within EVs can also contribute to the onset and
maintenance of drug resistance. Pigati et al. [80] have ob-
served that mammary epithelial cells released a different
subset of miRNAs compared to the ones which were
retained. They found that nearly 30 % of the released miR-
NAs in vitro did not reflect the cellular profile, indicating
that miRNAs are retained or released selectively. In par-
ticular, the malignant mammary epithelial cells released
most of their miRNA-451 into the environment. This con-
curs with findings from Kovalchuk et al. [81] who reported
that miRNA-451 targets the multidrug resistant gene
(mdr1), thereby down-regulating P-gp expression. Indeed,
transfection of the doxorubicin-resistant MCF-7 cells with
miRNA-451 resulted in an increased sensitivity of breast
cancer cells to the drug. It is tempting to speculate that
cancer cells have selective mechanisms to export certain
miRNAs in order to retain higher levels of P-gp necessary
to shuttle chemotherapeutic drugs out.
In this context, Chen et al. [82] showed that MCF-7
cells acquired an increased survival potential through
EVs released by corresponding docetaxel-resistant lines.
Microarray analysis revealed once again a specific subset
of miRNAs (including miRNA-222 and miRNA-452) in
the “resistant EVs”. The incubation of sensitive MCF-7
cells with resistant EVs resulted in a reduction of intra-
cellular PTEN and APC4 mRNAs known to be targeted
by miRNA-222 and miRNA-452, respectively. Although
protein levels had unfortunately not been analysed, the
authors speculated that these oncomiRs act by down-
regulating tumor suppressors. Furthermore, miRNA-21
and miRNA-155 from EVs were identified as important
players in the cross-talk between neuroblastoma cells and
monocytes. Co-culture experiments showed that miRNA-
21 released from neuroblastoma cells led to a TLR8- and
NF-кB-dependent secretion of EV-containing miRNA-155
from monocytes. Once taken up by neuroblastoma cells,
miRNA-155 targeted the telomeric repeat-binding factor 1
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Fig. 2 Drug-resistant cells can transfer the resistant phenotype through EVs. EVs released by drug-resistant cells contain proteins and miRNAs,
which partake in propagating resistance. Drug-sensitive cells become gradually resistant when they incorporate ”resistant EVs”: Resistant cells (1)
then over-express efflux pumps (P-gp) to eliminate anti-cancer drugs and produce more EVs, which again reflect the resistant phenotype of the
secreting cell. Once in the extracellular environment, these EVs can be taken up by sensitive recipient cells (2) through fusion, endocytosis or
binding to surface receptors. The released content acts on these cells, which in turn might also become drug-resistant (3). The lower part shows
example trends of dose–response curves to a cytotoxic drug, representative of drug-resistant cells (1), drug-sensitive cells (2) and the same
sensitive cells, which are becoming resistant after incubation with “resistant EVs” (3). The effectiveness of the drug to inhibit a specific biological function in
the cells (exemplified by the inhibition of cell growth) is expressed by the IC50 value. The higher this value, the more resistant the cells. The IC50 value of
cells which are acquiring the resistant phenotype would be in between the IC50 values of the other two conditions: IC50 (1) > IC50 (3) > IC50 (2)
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(TERF1) inducing an increased growth when the cells
were treated with cisplatin [83].
Drug efflux pumps
Among the different reasons for drug resistance in
malignancies, the up-regulation of efflux pumps such
as ABC transporters is often responsible for transport-
ing drugs out of cells [84]. Bebawy and colleagues [85]
demonstrated for the first time by flow cytometry that
EVs transfer functional P-glycoproteins (P-gp), well
characterised ABC transporters, from drug-resistant
to drug-sensitive human acute lymphoblastic leukemia
cells. Corcoran et al. [86] described the potential role
of EVs in transferring phenotypic changes associated
with docetaxel-resistance in prostate cancer cells: an
induced resistance in sensitive prostate cancer cells
cultured in the presence of EVs derived from resistant
cells was scored. The authors suggested P-gp to be po-
tentially involved in the newly-acquired resistance as
P-gp was expressed by both resistant prostate cells
and in corresponding EVs whereas it was undetectable
in the sensitive parental cells. Likewise, proteomic analysis
of EVs secreted from sensitive prostate cancer cells
compared to those from docetaxel-resistant cells re-
vealed a different profile, with “resistant EVs” being
once again enriched in P-gp and endophilin A [87]. The
presence of these proteins was also detected in the serum
of a small cohort of docetaxel-resistant patients. Hence,
these EV-transported proteins were proposed as predictive
biomarkers for therapeutic response or development of
drug resistance [87].
The relevance of P-gp delivery through EVs in the
process of transferring drug resistance was also confirmed
in breast cancer cells [88]. Here, P-gp was not directly
transported by EVs, but its transcription was activated by
the calcium permeable channel Transient Receptor Pro-
tein Channel 5 (TrpC5) in EVs released from adriamycin-
resistant breast cancer cells. Uptake of these vesicles
allowed the sensitive recipient cells to acquire the TrpC5
channel, leading to increased Ca2+-entry and the activation
of the Ca2+-dependent transcription factor NFATc3
(nuclear factor of activated T cells isoform c3), which in
turn was responsible for increased P-gp transcription [89].
Taken together, ABC transporters carried or induced by
EVs seem to play a prominent role in the development of
drug resistance by providing the cell with means to rid
themselves from drugs.
Several studies demonstrated the capability of EVs to
confer drug resistance; however little is known about the
role of EVs in inhibition of cancer cell proliferation dur-
ing chemotherapy. Bovy and colleagues [90] showed that
endothelial EVs taken up by breast cancer cells were able
to impair growth. In response to chemotherapeutic agents,
endothelial cells released EVs containing miRNA-503. The
presence of this miRNA within breast cancer cells induced
a reduction of their growth and invasion potential by
targeting cyclins D2 and D3. Twenty-two additional
up-regulated miRNAs were detected both in resistant
cells and corresponding EVs in the context of breast
cancer chemoresistance [91], 12 of which were signifi-
cantly up-regulated in biopsies taken after neoadjuvant
chemotherapy. Similar to miRNAs, long non coding
RNAs (lncRNAs) have also been described to transfer
drug resistance traits. The lncRNA linc-VLDLR enriched
in EVs released from HCC cells was able to modulate che-
motherapeutic response to sorafenib in recipient cancer
cells by upregulating the ABC transporters [92]. To date,
it remains to be proven whether inhibiting EV secretion
might be a therapeutic option to avoid responsive cancer
cells to become unresponsive.
Limitations of the functional analysis of EVs
Although there is little doubt that EVs and their cargo
can be transferred to be functionally active in recipient
cells, there are several, mostly technical issues which need
to be addressed to take this field one step further Standard
and generally accepted procedures and protocols should
be developed for:
 Sample preparation. EVs can be isolated by
different methods (ultracentrifugation, density
gradient ultracentrifugation and precipitation
reagents) and there is no generally accepted
procedure yet. In this context, Van Deun et al. have
clearly shown that the purification method of choice
will influence the purity of the vesicle population
and downstream results [6]. Although it is well
accepted by the community to isolate EVs through
density gradient ultracentrifugation, there is an
ongoing effort to find alternatives especially for
complex body fluids such as plasma or urine where
also the volume is a limiting factor. Moreover,
density gradient ultracentrifugation is time-consuming
and difficult to implement on a daily basis in clinical
routine. Size exclusion chromatography, ultrafiltration
and immunoprecipitation with specific antibodies
have recently been tested by several groups [93–95]
and might become convincing EV isolation methods
in future.
 Purity of the isolated EVs. The essential
requirements to define an EV population are:
i) providing a general overview of the protein
composition including proteins that should not be
present in EVs, ii) performing transmission
electron microscopy and nanoparticle-tracking
analysis and/or flow cytometry to understand the
purity of the isolates and using proper controls in
functional studies.
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 Quantification. The number of EV particles,
micrograms of proteins, nanograms of EV-RNA
need to be accurately determined.
 Sensitivity of visualisation of EV trafficking should
be further improved to allow for analysis of EV
functions under physiological conditions.
 Characterisation of EV cargos in different cellular
settings with a focus on protein, miRNA and lipid
profiles. The next task in this field will be to develop
sensitive and specific tools to overcome the above
issues. Only then will we be able to completely
understand the potential of EVs as new targets in
anti-neoplastic treatments and/or as new biomarkers
for early detection of pathological conditions.
Conclusions
The discovery of EVs as multi-component signaling com-
plexes mediating intercellular communication through the
delivery of molecules such as miRNAs and proteins has
raised a particular interest for the use of these microvesicles
as potential cancer biomarkers. Indeed, EVs present in body
fluids might represent a snapshot of the status of the cancer
cell at a specific time point providing highly sensitive and
specific cancer markers. The simultaneous production of
different subpopulations of EVs has been confirmed in
many publications [96–98]. In this context, the biggest
challenge the field is currently facing is the isolation and
precise characterisation of the different vesicle populations
and their corresponding functions. Questions such as i) dif-
ferent EV production and concentration in diseased versus
healthy cells, ii) a clear discrimination between cancer cell-
released EVs from surrounding stromal or healthy cells as
well as iii) specificity of EV uptake will all have to be ad-
dressed in future studies. Only when most of these points
are elucidated, can we begin to target certain subpopulation
of vesicles for therapeutic purposes.
Taken together in order to exploit EVs as potential
biomarkers or therapeutical targets, several technical
obstacles will have to be tackled in the near future: the
procedures for EV isolation and quantification need to
be standardised to avoid the observed discrepancies
and to dissect which other molecule classes are present
in EVs and whether they get sorted into vesicles by chance
or by targeted yet unknown processes. In addition, fur-
ther studies on lipid composition and alteration of EVs
will provide a more comprehensive understanding of
their role in the biological function of EVs and also
their potential impact on recipient cells. Nevertheless
and in support of the above reviewed evidence, EVs can
be regarded as interesting and important “homing
pigeons” carrying specific messages from one place to
the other. It remains to be shown how the cargo is
selected and sorted and whether these processes are
generally targeted or coincidental.
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